Hansoh Pharmaceutical Group Co (HKSE:03692) Change In Receivables : HK$374 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Change In Receivables?

Hansoh Pharmaceutical Group Co's change in receivables for the quarter that ended in Dec. 2023 was HK$105 Mil. It means Hansoh Pharmaceutical Group Co's Accounts Receivable declined by HK$105 Mil from Jun. 2023 to Dec. 2023 .

Hansoh Pharmaceutical Group Co's change in receivables for the fiscal year that ended in Dec. 2023 was HK$374 Mil. It means Hansoh Pharmaceutical Group Co's Accounts Receivable declined by HK$374 Mil from Dec. 2022 to Dec. 2023 .

Hansoh Pharmaceutical Group Co's Accounts Receivable for the quarter that ended in Dec. 2023 was HK$3,511 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Hansoh Pharmaceutical Group Co's Days Sales Outstanding for the six months ended in Dec. 2023 was 104.74.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Hansoh Pharmaceutical Group Co's liquidation value for the six months ended in Dec. 2023 was HK$22,212 Mil.

Hansoh Pharmaceutical Group Co Change In Receivables Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Change In Receivables Chart

Hansoh Pharmaceutical Group Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

445.38

-1,044.59

-672.66

101.00

373.81

Hansoh Pharmaceutical Group Co Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial									-607.47	751.68	-615.10	268.58	105.23

Hansoh Pharmaceutical Group Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$374 Mil.

Hansoh Pharmaceutical Group Co (HKSE:03692) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Hansoh Pharmaceutical Group Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3510.629	/	6117.056	*	91
=	104.74

2. In Ben Graham's calculation of liquidation value, Hansoh Pharmaceutical Group Co's accounts receivable are only considered to be worth 75% of book value:

Hansoh Pharmaceutical Group Co's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	27188.134	-	7923.669	+	0.75 * 3510.629	+	0.5 * 629.778
=	22,212

Hansoh Pharmaceutical Group Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Change In Receivables

Traded in Other Exchanges

3KY:Germany

Address

287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210

Website

https://www.hspharm.com

Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Executives

Cen Junda	2307 Founder of a discretionary trust who can infl
Cantrust (far East) Limited	2301 Trustee
Jqc Holding Limited	2201 Interest of corporation controlled by you
Jqc International Limited	2201 Interest of corporation controlled by you
Sun Yuan	2101 Beneficial owner
Harmonia Holding Investing (ptc) Limited	2201 Interest of corporation controlled by you
Stellar Infinity Company Ltd.	2101 Beneficial owner
Sunrise Investment Advisors Limited	2201 Interest of corporation controlled by you
Zhong Huijuan	2307 Founder of a discretionary trust who can infl
Apex Medical Company Ltd.	2101 Beneficial owner

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines